

Arcutis Biotherapeutics (NASDAQ:ARQT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has...
You can purchase shares of Arcutis Biotherapeutics (NASDAQ:ARQT) through any online brokerage.
Other companies in Arcutis Biotherapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Arcutis Biotherapeutics has a consensus price target of $34.20.
The stock price for Arcutis Biotherapeutics (NASDAQ: ARQT) is $26.6 last updated November 5, 2026 at 6:14 PM EST.
There are no upcoming dividends for Arcutis Biotherapeutics.
Arcutis Biotherapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Arcutis Biotherapeutics.
Arcutis Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical...